Zenas BioPharma, Inc.
ZBIO
Updated: 24/09/2026, 04:37:27
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
No summaries found.
- Share price
- $29.63
- Market cap
- $1.87B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Leon Oliver Moulder Jr.
- Employees
- 167
- IPO date
- 13/09/2024
- Beta
- -1.024
- Last dividend
- $0.00
- Day range
- $29.54 – $33.09
- 52-week range
- $13.50 – $44.60
- 1-day performance
- -10.35%
- 1-year performance
- 119.48%
- Current drawdown (1Y)
- -33.57%
- CIK
- 0001953926
- CUSIP
- 98937L105
- ISIN
- US98937L1052
- Created
- 07/12/2025, 15:13:22
- Last update
- 24/09/2026, 04:37:27
Track Zenas BioPharma, Inc. with an AI analyst
See which prediction-market events move ZBIO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
GlobeNewsWire • STOCK • 11/06/2026, 18:15:00
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
GlobeNewsWire • STOCK • 02/06/2026, 21:05:00
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
GlobeNewsWire • STOCK • 28/05/2026, 09:05:00
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
GlobeNewsWire • STOCK • 19/05/2026, 09:05:00
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
GlobeNewsWire • STOCK • 13/05/2026, 08:50:00
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026
Seeking Alpha • STOCK • 30/04/2026, 16:36:27
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
GlobeNewsWire • STOCK • 27/03/2026, 01:12:00
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
GlobeNewsWire • STOCK • 26/03/2026, 17:01:00
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
The Motley Fool • STOCK • 21/03/2026, 15:03:19
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
GlobeNewsWire • STOCK • 16/03/2026, 08:00:00
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
GlobeNewsWire • STOCK • 09/02/2026, 08:05:00
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewsWire • STOCK • 04/02/2026, 08:05:00